Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

CoBABATI

Financiado

Cofactor Binding Antibodies Basic Aspects and Therapeutic Innovations

The immune repertoire of healthy individuals contains a fraction of antibodies (Abs) that are able to bind with high affinity various endogenous or exogenous low molecular weight compounds, including cofactors essential for the ae... ver más

28/02/2023

INSERM

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-02-28

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-StG-2015: ERC Starting Grant

I+D

Cerrada hace 9 años

0% 100% 100%

2 Participantes

INSERM

1.26M€ | Lider

OSCAR D.O. CALIDAD 2005, S.L...

521.10K€ | Participante

Últimas noticias

30-11-2024: Cataluña Gestión For... Se ha cerrado la línea de ayuda pública: Gestión Forestal Sostenible para Inversiones Forestales Productivas para el organismo:

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

Duración del proyecto: 79 meses Fecha Inicio: 2016-07-12
Fecha Fin: 2023-02-28

Presupuesto del proyecto 1M€

Descripción del proyecto The immune repertoire of healthy individuals contains a fraction of antibodies (Abs) that are able to bind with high affinity various endogenous or exogenous low molecular weight compounds, including cofactors essential for the aerobic life, such as riboflavin, heme and ATP. Despite identification of cofactor-binding Abs as a constituent of normal immune repertoires, their fundamental characteristics and have not been systematically investigated. Thus, we do not know the origin, prevalence and physiopathological significance of cofactor-binding Abs. Moreover, the molecular mechanisms of interaction of cofactors with Abs are ill defined. Different proteins use cofactors to extend the chemistry intrinsic to the amino acid sequence of their polypeptide chain(s). Thus, one can speculate that the alliance of Abs with low molecular weight compounds results in the emergence of untypical properties of Abs and offers a strategy for designing a new generation of therapeutic Abs. Moreover, cofactor-binding Abs may be used for delivery of cytotoxic compounds to particular sites in the body, or for scavenging pro-inflammatory compounds. The principal goal of the present proposal is to gain a basic understanding on the fraction of cofactor-binding Abs in immune repertoires and to use this knowledge for the rational design of novel classes of therapeutic Abs. In this project, we will address the following questions: 1) understand the origin and prevalence of cofactor-binding Abs in immune repertoires; 2) characterize the molecular mechanisms of interaction of cofactors with Abs; 3) Understand the physiopathological roles of cofactor-binding Abs, and 4) use cofactor binding for the development of novel types of therapeutic Abs. A comprehensive understanding of various aspects of cofactor-binding Abs should lead to advances in fundamental understanding and in the development of innovative therapeutic and diagnostic tools.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores